An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers

Trial Profile

An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Abemaciclib; Merestinib
  • Indications Colorectal cancer; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 1 May 2019 to 1 May 2018.
    • 22 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
    • 21 Nov 2016 Planned End Date changed from 1 Aug 2019 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top